Nakajima T
Cancer Institute Hospital (C.I.H.), Division of Gastrointestinal Tract Surgery, Tokyo, Japan.
Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):82-6.
In a trial of adjuvant chemotherapy with mitomycin and 5-FU followed by oral UFT for T1 and T2 gastric cancer after curative gastrectomy, there was no significant difference in survival between the treated and control (surgery alone) groups (5-year survival rate, 82.9% control vs 85.8% treated). Although not significantly different, 5-year survival for patients with T2 cancer was slightly higher in the treated group than in the control group (76.9% control vs 83.0% treated). This finding suggests that T2 cancer should remain the target of further trials of adjuvant chemotherapy.
